Patient-reported outcome measures for depression or anxiety symptoms in patients with cardiovascular disease: A COSMIN systematic review.

J Psychosom ResAug 27, 2026 (epub)
Clinical ResearchCardiologyPsychiatry

Shisen Zhao, Yuanyuan Liu, Yang Ju et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the methodological quality and measurement properties of patient-reported outcome measures (PROMs) for depression and anxiety in adults with cardiovascular disease (CVD). A total of 66 studies were analyzed, identifying six PROMs that met COSMIN Category A criteria. The review highlights the need for careful selection of PROMs based on context and purpose.

Key findings

  • Six PROMs met COSMIN Category A criteria for quality assessment.
  • Only 24 studies employed confirmatory factor analysis or Rasch analysis.
  • Four instruments were classified as Category C due to insufficient structural validity.
  • Content validity evidence was largely indeterminate or of limited certainty.

Why it matters

Understanding the quality of PROMs for depression and anxiety in CVD patients is crucial for accurate assessment and management of these comorbid conditions, which can significantly impact patient outcomes.

Source

PubMed · PMID 42664848

Published in J Psychosom Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.